Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus INDIUM IN 111 PENTETREOTIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus INDIUM IN 111 PENTETREOTIDE KIT.
FLUORINE F-18 vs INDIUM IN-111 PENTETREOTIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical